ArticleFrontiers in medicine2024
Demographic features, clinical characteristics, and comorbid relation in hidradenitis suppurativa: a population-based study.
Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Decreased HDL-C in hidradenitis suppurativa: association with systemic inflammatory phenotype and implications for risk stratification.Lipids in health and disease · 2026Article
- mRNAome Analysis of Whole Blood of Patients with Psoriatic Arthritis, Ankylosing Spondylitis, and Rheumatoid Arthritis.Current rheumatology reviews · 2026Review
- When hidradenitis suppurativa flares mimic sepsis: A case series of 6 hospitalized patients.JAAD case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/objective: Hidradenitis suppurativa (HS) is a chronic inflammatory disease affecting apocrine gland areas, characterized by painful nodules and abscesses that may result in sinus tracts and scarring. The global prevalence of HS is increasing due to heightened awareness, improved diagnostic methods, rising obesity rates, and higher smoking prevalence. This study aimed to describe the epidemiological, clinical, and comorbid characteristics of HS patients. Methodology: This retrospective descriptive cross-sectional study included 193 outpatients aged between 15 and 73 years who visited a tertiary HS clinic between 2017 and 2022. Demographic, clinical, and comorbid characteristics were recorded and analyzed using chi-square and ordinal regression methods. Results: The mean age was 34.5 ± 12.1 years, with a mean disease duration of 5.9 ± 6.7 years. According to the Hurley classification, 61.1, 24.4, and 14.5% were stages I, II, and III, respectively. Comorbidities were present in 48.2% of patients, with psychiatric disorders (19.2%), diabetes mellitus (14%), and hypertension (9.3%) being most common. Disease duration, smoking, male gender, and atypical localization were associated with increased disease severity. Conclusion: Geographic and cultural factors influence the prevalence, severity, and management of HS, necessitating tailored treatment. Effective management requires multidisciplinary screening for early detection and prevention of comorbidities, including psychiatric disorders, cardiovascular conditions, and metabolic syndrome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.